Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial | Zendy

Takashi Kadowaki | Zendy; Guang Wang | Zendy; Julio Rosenstock | Zendy; Daisuke Yabe | Zendy; Yongde Peng | Zendy; Keizo Kanasaki | Zendy; Yiming Mu | Zendy; Michaela Mattheus | Zendy; Annett Keller | Zendy; Tomoo Okamura | Zendy; Odd Erik Johansen | Zendy; Nikolaus Marx | Zendy

Open Access

Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial

Author(s) -

Takashi Kadowaki,

Guang Wang,

Julio Rosenstock,

Daisuke Yabe,

Yongde Peng,

Keizo Kanasaki,

Yiming Mu,

Michaela Mattheus,

Annett Keller,

Tomoo Okamura,

Odd Erik Johansen,

Nikolaus Marx

Publication year - 2020

Publication title -

diabetology international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.411

H-Index - 17

eISSN - 2190-1686

pISSN - 2190-1678

DOI - 10.1007/s13340-020-00447-5

Subject(s) - linagliptin , glimepiride , medicine , hazard ratio , dipeptidyl peptidase 4 inhibitor , type 2 diabetes , mace , dulaglutide , subgroup analysis , type 2 diabetes mellitus , diabetes mellitus , randomized controlled trial , population , myocardial infarction , confidence interval , endocrinology , liraglutide , percutaneous coronary intervention , environmental health

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research